What We're Reading: Page 128
Industry reads hand-picked by our editors
Aug 12, 2022
-
The Economist
After a covid-fuelled adrenaline rush, biotech is crashing
-
Reuters
Rotavirus childhood vaccine shortage hits four African countries
-
The New York Times
Hospital and Drugmaker Move to Build Vast Database of New Yorkers’ DNA
-
STAT
Eli Lilly statement on Indiana abortion law sends disingenuous message
Aug 11, 2022
-
Politico
Bottling the monkeypox vaccine could take until early 2023
-
Endpoints News
Cerevel takes the public offering route, with a twist — raising big money thanks to rival data
-
The Atlantic
America’s New Monkeypox Vaccine Strategy Rests on a Single Study
-
Reuters
Aspen COVID vaccine lines risk going idle as J&J orders dwindle
Aug 10, 2022
-
Bloomberg
FDA Warns Diabetes Drug Sitagliptin May Contain Cancer-Causing Carcinogen
-
Nature
Long-COVID treatments: why the world is still waiting
-
ROI-NJ
Catalent to acquire Metrics Contract Services for $475M
-
MIT Technology Review
Psychedelics are having a moment and women could be the ones to benefit
Aug 09, 2022
-
Boston Business Journal
Biogen seeks to shrink real estate in Kendall Square, suburbs
-
Politico
Monkeypox dose sparing? Biden admin looks to NIH-funded study for clues.
-
FierceBiotech
Genentech tries again on diversity aim for Alzheimer’s program
Aug 08, 2022
Aug 05, 2022
-
Bloomberg
Alphabet’s DeepMind Shows AI’s Value in Speeding Drug Discovery
-
Reuters
China’s Innovent Biologics secures over $300 million investment from Sanofi
-
Politico
Pharma group leader says Dems who vote for reconciliation bill ‘won’t get a free pass’
-
Nature
Billions more for US science: how the landmark spending plan will boost research
Aug 04, 2022
-
Bloomberg
Global Blood Therapeutics Is Said to Draw Takeover Interest
-
The Wall Street Journal
Eli Lilly’s Covid-19 Antibody Treatment to Be Sold Commercially
-
FiercePharma
Thermo Fisher marches on with $650M bioprocessing expansion
Previous
